Dianthus Therapeutics, Inc.DNTHNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +135.06% | +190.15% | +33.07% | -89.64% | -81.77% |
| Gross Profit Growth | +140.00% | +190.15% | +33.07% | -89.64% | -81.77% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +776.32% | +673.35% | +39.45% | +4.66% | +10.39% |
| Weighted Average Shares Diluted Growth | +776.32% | +673.35% | +39.45% | +4.66% | +10.39% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -1520.64% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -1396.71% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +72.17% | +68.83% | +14.16% | -97.67% | +286.70% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +84.06% | +108.47% | -8.86% | -11.62% | +63.01% |
| Book Value per Share Growth | -78.38% | -73.01% | -36.77% | -19.16% | +46.50% |
| Debt Growth | -53.58% | +154.87% | +180.89% | +226.78% | +313.18% |
| R&D Expense Growth | +220.90% | +200.80% | +106.48% | +45.27% | +27.19% |
| SG&A Expenses Growth | -25.00% | +47.43% | +30.09% | +47.89% | +25.54% |